NCT07287397

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2025-12-19Est. Completion: 2027-10-15

Enrollment target: 12 participants

Locations

St Joseph's Hospital and medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States
University of California San Diego Medical Center, San Diego, California, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
University of Miami School of Science, Miami, Florida, United States
Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, Boston, Massachusetts, United States
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
UZ Leuven, Leuven, Belgium
UMC Utrecht, Utrecht, Netherlands
Kings College Hospital, London, United Kingdom
Royal Hallamshire Hospital, Sheffield, United Kingdom

Contact

Dr Olga Uspenskaya Chief medical Officer, VectorY Therapeutics, M.D; PhD

Amyotrophic Lateral Sclerosis

Given the role of adaptive immunity in ALS, the pathogenicity of some clostridial strains on motorneurons, the putative …

Roma, ItalyCompleted Feb 1, 2025

Amyotrophic Lateral Sclerosis

The goal of this clinical trial is to evaluate whether low-dose colchicine can slow disease progression in patients with…

Milan, ItalyEst. completion May 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.